<GlossaryTerm id="CDR0000718939"><TermName>orantinib</TermName><TermPronunciation>(oh-RAN-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. Orantinib blocks proteins involved in the growth and spread of cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called SU006668 and SU6668.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000734566" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;orantinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000734565" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;orantinib&quot;" language="es" id="_4"/><SpanishTermName>orantinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer. El orantinib bloquea proteínas que participan en la multiplicación y diseminación de células cancerosas. También es posible que evite la formación de los vasos sanguíneos nuevos que los tumores necesitan para crecer. Es un tipo de antiangiogénico y de inhibidor de tirosina–cinasas. También se llama SU006668 y SU6668.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2012-02-15</DateFirstPublished><DateLastModified>2012-02-14</DateLastModified></GlossaryTerm>
